Phase II Trial of Clofarabine and Daunorubicin as Induction Therapy for Acute Myeloid Leukemia Patients Greater Than or Equal to 60 Years of Age

Leukemia Research- United Kingdom

doi 10.1016/j.leukres.2013.07.036

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Clofarabine, Idarubicin, and Cytarabine (CIA) as Frontline Therapy for Patients <= 60 Years With Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Clofarabine Combinations as Acute Myeloid Leukemia Salvage Therapy

Cancer
Cancer ResearchOncology
2008English

Acute Myeloid Leukemia in Patients Older Than 60 Year

Journal of Tumor Medicine & Prevention
2018English

Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older With Acute Myeloid Leukemia

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2013English

A Phase I Study of Tipifarnib Combined With Conventional Induction and Consolidation Therapy for Previously Untreated Patients With Acute Myeloid Leukemia Aged 60 Years and Over

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2008English

Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 With Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Biology of Blood and Marrow Transplantation
TransplantationHematology
2017English

“Epigenetic” Modification as Therapy for Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2017English

Therapy of Acute Myeloid Leukemia

2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy